ArticlePloS one2025
Exposure to volatile organic compounds increases the risk of sarcopenia: Insights into association and mechanism.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVolatile organic compounds (VOCs) are ubiquitous in our environment, and their associations with sarcopenia are unknown. The aim of this study is to evaluate the association between VOCs exposure and sarcopenia.
methodsData from 2429 U.S. adults (aged ≥ 20 years) were extracted from the NHANES (2011-2018). Logistic regression, LASSO, Weighted Quantile Sum (WQS) and Bayesian Kernel Machine regression (BKMR) analyses were used to assess the associations between VOCs and sarcopenia. Mediation analysis tested roles of inflammation and oxidative stress in this association. The underlying mechanisms were further investigated through database enrichment analysis, molecular docking, and molecular dynamics simulations.
resultsAmong the 2429 adults included, 1213 (49.9%) were male, 1216 (50.1%) were female, and the median age was 39 years (interquartile range, 29-49 years), with a prevalence of sarcopenia of 8.03%. According to the logistic analysis, nine mVOCs were significantly associated with sarcopenia, with N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA) identified as a potential independent risk factor (odds ratio [OR], 4.51 [95% CI: 1.7-12.1]). WQS analysis revealed a positive association between LASSO-selected 12 mVOCs and sarcopenia (OR 1.39 [95% CI: 1.17-1.90]). BKMR analysis further confirmed this association, with DHBMA showing a significant contribution. Mediation analysis confirmed that inflammation and oxidative stress exert mediating effects. GO and KEGG enrichment analyses indicated that its effects are exerted through the TNF and PI3K-Akt signaling pathways, and that DHBMA binds stably to AKT1.
conclusionThis nationally representative cross-sectional study revealed a positive correlation between exposure to mVOCs and sarcopenia via TNF and PI3K-Akt signaling pathways. DHBMA plays a potentially pivotal role in this association.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.